Affinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026

AFTX-201 is a potential best-in-class investigational genetic medicine for the treatment of BAG3-associated dilated cardiomyopathy (DCM) WALTHAM, Mass. – October 9, 2026 – Affinia Therapeutics (“Affinia”), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that AFTX-201 preclinical and […] The post Affinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Sc